| Basics |
Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Its drug candidates are PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357.
|
| IPO Date: |
April 20, 2012 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$260.42M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.23 | 3.13%
|
| Avg Daily Range (30 D): |
$0.11 | 2.28%
|
| Avg Daily Range (90 D): |
$0.12 | 2.80%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.6M |
| Avg Daily Volume (30 D): |
.43M |
| Avg Daily Volume (90 D): |
.48M |
| Trade Size |
| Avg Trade Size (Sh.): |
117 |
| Avg Trade Size (Sh.) (30 D): |
87 |
| Avg Trade Size (Sh.) (90 D): |
98 |
| Institutional Trades |
| Total Inst.Trades: |
3,689 |
| Avg Inst. Trade: |
$2.06M |
| Avg Inst. Trade (30 D): |
$.83M |
| Avg Inst. Trade (90 D): |
$.88M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.63M |
| Avg Closing Trade (30 D): |
$.83M |
| Avg Closing Trade (90 D): |
$.85M |
| Avg Closing Volume: |
77.2K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$.12
|
$.06
|
|
Diluted EPS
|
|
$.12
|
$.06
|
|
Revenue
|
$
|
$ 52.44M
|
$ 46.01M
|
|
Gross Profit
|
$
|
$ 40.14M
|
$ 35.45M
|
|
Net Income / Loss
|
$
|
$ 5.86M
|
$ 2.97M
|
|
Operating Income / Loss
|
$
|
$ 6.64M
|
$ 3.98M
|
|
Cost of Revenue
|
$
|
$ 12.3M
|
$ 10.56M
|
|
Net Cash Flow
|
$
|
$ -8.37M
|
$ -6.19M
|
|
PE Ratio
|
|
|
|
|
|
|
